Captrust Financial Advisors Genetic Technologies LTD Transaction History

Captrust Financial Advisors

  • $33 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
BUY
$0.0 - $0.01 $0 - $35
3,500 New
3,500 $7,000

About GENETIC TECHNOLOGIES LTD

GENE Quotes by TradingView
  • Ticker GENE
  • Exchange OTC
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 15,389,900
  • Market Cap $11.9M
  • Description
  • Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to ...
More about GENE
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email